Ponatinib (trade name Iclusig previously AP24534) is an Food and Drug Administration–approved oral drug candidate developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML those that have the T315I mutation are resistant to current therapies such as imatinib.
This page contains content from the copyrighted Wikipedia article "Ponatinib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
